Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(ramucirumab)
639 results
  • Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. [Review]
    Medicina (Kaunas) 2019; 55(10)Longo V, Brunetti O, … Argentiero A
  • Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide. A total of 70-80% of patients are diagnosed at an advanced stage with a dismal prognosis. Sorafenib had been the standardcare for almost a decade until 2018 when the Food and Drug Administration approved an alternative first-line agent namely lenvatinib. Cabozantinib, regorafen…
  • The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. [Journal Article]
    Expert Opin Biol Ther 2019; :1-8Macarulla T, Montagut C, … Tabernero J
  • Introduction: In colorectal cancer, anti-VEGF agents have demonstrated a survival benefit when combined with chemotherapy. However, development of resistance is very common. One of the mechanisms is due not to a failure in the VEGFR blockade, but rather to development of compensatory mechanisms of resistance, such as hypoxia-triggered upregulation of other proangiogenic factors, like placental gr…
  • Treatment Lines in Hepatocellular Carcinoma. [Review]
    Visc Med 2019; 35(4):266-272Wege H, Li J, Ittrich H
  • Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and the second most lethal malignancy worldwide. In the Western world, HCC predominantly develops in patients with liver cirrhosis. Therefore, application of locoregional interventions and systemic agents should be based on an interdisciplinary evaluation, most importantly, taking the functional liver reserve into account. T…
  • Immuno-PET imaging of VEGFR-2 expression in prostate cancer with 89Zr-labeled ramucirumab. [Journal Article]
    Am J Cancer Res 2019; 9(9):2037-2046Li M, Jiang D, … Cai W
  • The detection and monitoring of prostate cancer (PrCa) malignancies using most of the conventional strategies is challenging. As an over-expressed biomarker of PrCa, the vascular endothelial growth factor receptor 2 (VEGFR-2) can be delineated by non-invasive imaging to address such issue. Herein, we report the positron emission tomography (PET) of VEGFR-2 expression in a PrCa mice models by comp…
New Search Next